Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.04
DGX's Cash to Debt is ranked lower than
57% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. DGX: 0.04 )
DGX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.04

Equity to Asset 0.42
DGX's Equity to Asset is ranked higher than
57% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. DGX: 0.42 )
DGX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.62
Current: 0.42

0.3
0.62
Interest Coverage 9.10
DGX's Interest Coverage is ranked higher than
50% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. DGX: 9.10 )
DGX' s 10-Year Interest Coverage Range
Min: 1.82   Max: 16.85
Current: 9.1

1.82
16.85
F-Score: 6
Z-Score: 2.87
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.64
DGX's Operating margin (%) is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. DGX: 20.64 )
DGX' s 10-Year Operating margin (%) Range
Min: -37.2   Max: 20.64
Current: 20.64

-37.2
20.64
Net-margin (%) 11.88
DGX's Net-margin (%) is ranked higher than
90% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. DGX: 11.88 )
DGX' s 10-Year Net-margin (%) Range
Min: -38.73   Max: 11.88
Current: 11.88

-38.73
11.88
ROE (%) 21.50
DGX's ROE (%) is ranked higher than
94% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.60 vs. DGX: 21.50 )
DGX' s 10-Year ROE (%) Range
Min: -116.19   Max: 21.81
Current: 21.5

-116.19
21.81
ROA (%) 9.49
DGX's ROA (%) is ranked higher than
88% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. DGX: 9.49 )
DGX' s 10-Year ROA (%) Range
Min: -44.87   Max: 11.87
Current: 9.49

-44.87
11.87
ROC (Joel Greenblatt) (%) 136.45
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. DGX: 136.45 )
DGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -113.86   Max: 136.45
Current: 136.45

-113.86
136.45
Revenue Growth (%) 4.00
DGX's Revenue Growth (%) is ranked higher than
68% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. DGX: 4.00 )
DGX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 15.4
Current: 4

0
15.4
EBITDA Growth (%) 9.40
DGX's EBITDA Growth (%) is ranked higher than
78% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. DGX: 9.40 )
DGX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 44.5
Current: 9.4

0
44.5
EPS Growth (%) 9.40
DGX's EPS Growth (%) is ranked higher than
79% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. DGX: 9.40 )
DGX' s 10-Year EPS Growth (%) Range
Min: 0   Max: 62.3
Current: 9.4

0
62.3
» DGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

DGX Guru Trades in Q3 2013

Paul Tudor Jones 3,600 sh (New)
John Rogers 48,939 sh (+557.34%)
Jeff Auxier 61,050 sh (+478.67%)
HOTCHKIS & WILEY 2,095,900 sh (+61.93%)
Joel Greenblatt 44,062 sh (+41.25%)
Chuck Royce 155,850 sh (+28.8%)
Diamond Hill Capital 1,954,720 sh (+3.14%)
Richard Pzena 670,650 sh (+0.79%)
Murray Stahl 6,650 sh (+0.76%)
David Dreman 40,690 sh (+0.03%)
Brian Rogers 2,200,000 sh (unchged)
Bernard Horn 42,933 sh (unchged)
Robert Olstein 83,000 sh (unchged)
Ray Dalio Sold Out
Alan Fournier 425,700 sh (-17.72%)
Jeremy Grantham 1,466,042 sh (-20.67%)
Steven Cohen 4,302 sh (-59.49%)
Jim Simons 127,700 sh (-69.49%)
» More
Q4 2013

DGX Guru Trades in Q4 2013

Steven Cohen 63,695 sh (+1380.59%)
Paul Tudor Jones 26,689 sh (+641.36%)
Joel Greenblatt 279,188 sh (+533.63%)
John Rogers 268,053 sh (+447.73%)
Richard Pzena 1,215,050 sh (+81.17%)
Jeff Auxier 80,350 sh (+31.61%)
Brian Rogers 2,750,000 sh (+25%)
Robert Olstein 93,000 sh (+12.05%)
Murray Stahl 7,400 sh (+11.28%)
Chuck Royce 171,100 sh (+9.79%)
Diamond Hill Capital 2,049,646 sh (+4.86%)
Bernard Horn 42,933 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY 2,017,600 sh (-3.74%)
David Dreman 29,218 sh (-28.19%)
Alan Fournier 237,778 sh (-44.14%)
Jeremy Grantham 377,008 sh (-74.28%)
» More
Q1 2014

DGX Guru Trades in Q1 2014

Chris Davis 102,337 sh (New)
Larry Robbins 1,951,300 sh (New)
Manning & Napier Advisors, Inc 191,490 sh (New)
Ray Dalio 78,977 sh (New)
Louis Moore Bacon 7,800 sh (New)
Paul Tudor Jones 406,067 sh (+1421.48%)
Steven Cohen 110,044 sh (+72.77%)
David Dreman 48,748 sh (+66.84%)
Bernard Horn 61,733 sh (+43.79%)
HOTCHKIS & WILEY 2,495,500 sh (+23.69%)
Chuck Royce 188,600 sh (+10.23%)
John Rogers 295,159 sh (+10.11%)
Brian Rogers 3,000,000 sh (+9.09%)
Robert Olstein 100,000 sh (+7.53%)
Murray Stahl 7,850 sh (+6.08%)
Jeff Auxier 80,350 sh (unchged)
Alan Fournier Sold Out
Richard Pzena 972,200 sh (-19.99%)
Joel Greenblatt 76,412 sh (-72.63%)
Jeremy Grantham 91,500 sh (-75.73%)
Diamond Hill Capital 253,642 sh (-87.63%)
» More
Q2 2014

DGX Guru Trades in Q2 2014

Scott Black 220 sh (New)
Chris Davis 4,672,681 sh (+4465.97%)
Louis Moore Bacon 14,460 sh (+85.38%)
John Rogers 352,928 sh (+19.57%)
HOTCHKIS & WILEY 2,523,400 sh (+1.12%)
Manning & Napier Advisors, Inc 193,424 sh (+1.01%)
Brian Rogers 3,000,000 sh (unchged)
Jeremy Grantham Sold Out
Larry Robbins Sold Out
Chuck Royce 187,500 sh (-0.58%)
Jeff Auxier 79,000 sh (-1.68%)
Murray Stahl 7,050 sh (-10.19%)
Robert Olstein 82,000 sh (-18%)
David Dreman 35,982 sh (-26.19%)
Diamond Hill Capital 124,800 sh (-50.8%)
Richard Pzena 431,100 sh (-55.66%)
Ray Dalio 13,545 sh (-82.85%)
Joel Greenblatt 4,384 sh (-94.26%)
Paul Tudor Jones 8,400 sh (-97.93%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -94.26%0.06%$55.5 - $61.75 $ 62.246%4384
David Dreman 2014-06-30 Reduce -26.19%0.06%$55.5 - $61.75 $ 62.246%35982
Ray Dalio 2014-06-30 Reduce -82.85%0.03%$55.5 - $61.75 $ 62.246%13545
Scott Black 2014-06-30 New Buy$55.5 - $61.75 $ 62.246%220
Joel Greenblatt 2014-03-31 Reduce -72.63%0.26%$50.8 - $57.99 $ 62.2416%76412
David Dreman 2014-03-31 Add 66.84%0.09%$50.8 - $57.99 $ 62.2416%48748
Ray Dalio 2014-03-31 New Buy0.04%$50.8 - $57.99 $ 62.2416%78977
Joel Greenblatt 2013-12-31 Add 533.63%0.3%$52.79 - $63.7 $ 62.245%279188
David Dreman 2013-12-31 Reduce -28.19%0.06%$52.79 - $63.7 $ 62.245%29218
Joel Greenblatt 2013-09-30 Add 41.25%0.03%$57.96 - $62.48 $ 62.244%44062
Ray Dalio 2013-09-30 Sold Out $57.96 - $62.48 $ 62.244%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.00
DGX's P/E(ttm) is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 12.00 )
DGX' s 10-Year P/E(ttm) Range
Min: 9.13   Max: 31.21
Current: 12

9.13
31.21
P/B 2.20
DGX's P/B is ranked higher than
81% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.38 vs. DGX: 2.20 )
DGX' s 10-Year P/B Range
Min: 1.87   Max: 4.43
Current: 2.2

1.87
4.43
P/S 1.27
DGX's P/S is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.42 vs. DGX: 1.27 )
DGX' s 10-Year P/S Range
Min: 1.03   Max: 2.21
Current: 1.27

1.03
2.21
PFCF 17.90
DGX's PFCF is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 17.90 )
DGX' s 10-Year PFCF Range
Min: 8.22   Max: 21.5
Current: 17.9

8.22
21.5
EV-to-EBIT 8.85
DGX's EV-to-EBIT is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 8.85 )
DGX' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 14.3
Current: 8.85

7.2
14.3
PEG 1.70
DGX's PEG is ranked higher than
94% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 1.70 )
DGX' s 10-Year PEG Range
Min: 0.45   Max: 4.28
Current: 1.7

0.45
4.28
Shiller P/E 15.50
DGX's Shiller P/E is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 15.50 )
DGX' s 10-Year Shiller P/E Range
Min: 12.83   Max: 48.01
Current: 15.5

12.83
48.01
Current Ratio 1.20
DGX's Current Ratio is ranked higher than
50% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. DGX: 1.20 )
DGX' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.15
Current: 1.2

0.74
2.15
Quick Ratio 1.11
DGX's Quick Ratio is ranked higher than
52% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. DGX: 1.11 )
DGX' s 10-Year Quick Ratio Range
Min: 0.7   Max: 2.03
Current: 1.11

0.7
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.02
DGX's Dividend Yield is ranked higher than
78% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. DGX: 2.02 )
DGX' s 10-Year Dividend Yield Range
Min: 0.35   Max: 2.36
Current: 2.02

0.35
2.36
Dividend Payout 0.24
DGX's Dividend Payout is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.24 )
DGX' s 10-Year Dividend Payout Range
Min: 0.09   Max: 0.86
Current: 0.24

0.09
0.86
Dividend growth (3y) 55.40
DGX's Dividend growth (3y) is ranked higher than
94% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. DGX: 55.40 )
DGX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 55.4
Current: 55.4

0
55.4
Yield on cost (5-Year) 8.48
DGX's Yield on cost (5-Year) is ranked higher than
87% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DGX: 8.48 )
DGX' s 10-Year Yield on cost (5-Year) Range
Min: 1.48   Max: 10.01
Current: 8.48

1.48
10.01
Share Buyback Rate 4.80
DGX's Share Buyback Rate is ranked higher than
97% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. DGX: 4.80 )
DGX' s 10-Year Share Buyback Rate Range
Min: 0   Max: -17.7
Current: 4.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
DGX's Price/DCF (Projected) is ranked higher than
98% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.80 )
DGX' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 4.46
Current: 0.8

0.65
4.46
Price/Median PS Value 0.90
DGX's Price/Median PS Value is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. DGX: 0.90 )
DGX' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.6
Current: 0.9

0.23
1.6
Price/Peter Lynch Fair Value 1.60
DGX's Price/Peter Lynch Fair Value is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 1.60 )
DGX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 3.48
Current: 1.6

0.62
3.48
Earnings Yield (Greenblatt) 11.00
DGX's Earnings Yield (Greenblatt) is ranked higher than
85% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. DGX: 11.00 )
DGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7   Max: 13.8
Current: 11

7
13.8
Forward Rate of Return (Yacktman) 13.85
DGX's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. DGX: 13.85 )
DGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.9   Max: 33.9
Current: 13.85

11.9
33.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, LIFE, ENZ, IDXX » details
Traded in other countries:QDI.Germany
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing, information and services, providing insights that enable patients and physicians to make better healthcare decisions. The Company offers U.S. patients and physicians the broadest access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. It provides interpretive consultation through the largest medical and scientific staff in the industry, including hundreds of M.D.s and Ph.D.s, primarily located in the United States. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and provider of risk assessment services for the life insurance industry. The Company is also a provider of testing for clinical trials and testing for drugs of abuse. The Company's diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. The Company empowers healthcare organizations and clinicians with state-of-the-art information technology solutions that can improve patient care and medical practice. It is the commercial clinical testing company. It offers customers the access to the extensive test menu of clinical and anatomic pathology tests in the United States. It performs routine testing through its network of major laboratories and rapid response laboratories. It is a provider of cancer diagnostics, including anatomic pathology services, in the United States. Gene-based and other esoteric tests increasingly are ordered by physicians to assist them in the diagnostic process, to establish a prognosis and to choose or monitor a therapeutic regimen. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. The Company is an innovator in the clinical testing industry, with capabilities ranging from early discovery to validation of clinical tests. It develops tests at its laboratories, such as Quest Diagnostics Nichols Institute; it also develops innovative techniques in anatomic pathology. Its industry remains fragmented and highly competitive. The Company mainly competes with three types of clinical testing providers: hospital-affiliated laboratories, other commercial clinical laboratories and physician-office laboratories. The Company's businesses are subject to or impacted by extensive and frequently changing laws and regulations in the United States at both the federal and state levels and the other jurisdictions in which it conduct business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
Bernard Horn Comments on Quest Diagnostics Aug 07 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S May 28 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/S May 13 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 05 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S Apr 29 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 28 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 
Morning Coffee: Stocks at Historical Low P/B and P/S Mar 25 2014 
Diamond Hill Capital Comments on Quest Diagnostics Mar 05 2014 

More From Other Websites
Quest Diagnostics Declares Quarterly Cash Dividend Aug 20 2014
Air Methods Navigates To Grow Medical Flight Business Aug 18 2014
Quest Diagnostics Declares Quarterly Cash Dividend Aug 15 2014
Myriad Genetics: Not as Bad as It Looks? Aug 13 2014
Myriad Genetics Guidance Disappoints, Q4 Edges Views Aug 12 2014
Myriad Genetics' Earnings Face 'Angelina Jolie' Comps Aug 11 2014
QUEST DIAGNOSTICS INC Financials Aug 08 2014
Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation (CTSO), Interviews with The... Aug 01 2014
QUEST DIAGNOSTICS INC Files SEC form 10-Q, Quarterly Report Jul 31 2014
FDA To Regulate Thousands Of Cancer, Genetic, And Other Diagnostics Jul 31 2014
[video] What's it like working with Carl Icahn? Jul 31 2014
[video] Hologic's 3D medical breakthrough: CEO Jul 31 2014
Quest Diagnostics Beats on Q2 Earnings & Revenues, Ups View Jul 25 2014
Quest Diagnostics Adds Vicky Gregg to Board of Directors Jul 24 2014
Quest Diagnostics Reports Second Quarter 2014 Financial Results Jul 24 2014
[$$] Quest Diagnostics Revenue Rises 4.8% Jul 24 2014
QUEST DIAGNOSTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 24 2014
Q2 2014 Quest Diagnostics Earnings Release - Before Market Open Jul 24 2014
Quest Diagnostics Reports Second Quarter 2014 Financial Results Jul 24 2014
QUEST DIAGNOSTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide